Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 6/20 | 0.79 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.31 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3967632 | 0.88 | CRHR1 (1.00) | CRHR1CRHR2PDE10AROCK1CYP17A1 | |
| SCHEMBL3964382 | 0.85 | CRHR1 (0.79) | CRHR1CRHR2PDE10AROCK1CYP17A1 | |
| SCHEMBL4690737 | 0.83 | CRHR1 (0.57) | CRHR1PDE10APIK3CAROCK1 | |
| SCHEMBL3970579 | 0.82 | CRHR1 (0.87) | CRHR1CRHR2PDE10AROCK1CYP17A1 | |
| SCHEMBL3968166 | 0.81 | CRHR1 (0.75) | CRHR1CRHR2ROCK1SMPD3 | |
| SCHEMBL3963171 | 0.80 | CRHR1 (0.84) | CRHR1CRHR2PDE10AROCK1CYP17A1 | |
| SCHEMBL3967558 | 0.78 | CRHR1 (0.81) | CRHR1CRHR2ROCK1SMPD3 | |
| SCHEMBL3965603 | 0.78 | CRHR1 (0.60) | CRHR1PDE10ASMPD3 | |
| SCHEMBL3963749 | 0.77 | CRHR1 (0.79) | CRHR1CRHR2ROCK1 | |
| SCHEMBL13763338 | 0.77 | CRHR1 (0.78) | CRHR1CRHR2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557103-B2 | Imidazopyridazine compounds | ELI LILLY AND COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557103-B2 | Imidazopyridazine compounds | ELI LILLY AND COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557103-B2 | Imidazopyridazine compounds | ELI LILLY AND COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-20080153828-A1 | Imidazopyridazine Compounds | ELI LILLY AND COMPANY | 2008-06-26 | — | — | US | disclosed |
| US-20080153828-A1 | Imidazopyridazine Compounds | ELI LILLY AND COMPANY | 2008-06-26 | — | — | US | disclosed |
| US-20080153828-A1 | Imidazopyridazine Compounds | ELI LILLY AND COMPANY | 2008-06-26 | — | — | US | disclosed |
| EP-1879896-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006107784-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153828-A1 | Imidazopyridazine Compounds | CRHR1, CRH, CRHR2 | CRHR1 1/4885CRHR2 3/4885PDE10A 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.